Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jieyuyihao prescription is a Traditional Chinese Medicine (TCM) herbal formula developed by Beijing Anding Hospital, Capital Medical University, for the treatment of major depressive disorder (MDD). It is specifically indicated for patients diagnosed with the TCM syndrome of liver depression and qi stagnation. The formula is being evaluated as an adjunctive therapy to standard psychiatric care to improve depressive symptoms, safety profiles, and biological markers. As a complex herbal mixture, its pharmacological effects are thought to involve the regulation of the neuroendocrine system and the modulation of neurotransmitter levels associated with mood regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jieyuyihao prescription.